Formulary Tier Placement for Commonly Prescribed Branded Drugs: Benchmarking and Creation of a Preferred Placement IndexByC. Daniel Mullins, PhD,Francis B. Palumbo, PhD,Mojdeh Saba, BSJune 1st 2007
Effects of Benefit Design Change Across 5 Disease StatesByDiana I. Brixner, PhD, RPh,Vijay N. Joish, PhD,Gary M. Oderda, PharmD, MPH,Steven G. Avey, RPh,Douglas M. Hanson, MA,H. Eric Cannon, PharmDJune 1st 2007
Consumer Response to Dual Incentives Under Multitiered Prescription Drug FormulariesByBoyd H. Gilman, PhD,John Kautter, PhDJune 1st 2007
Incentive Formularies and Changes in Prescription Drug SpendingByBruce E. Landon, MD, MBA,Meredith B. Rosenthal, PhD,Sharon-Lise T. Normand, PhD,Claire Spettell, PhD,Adam Lessler, BA,Howard R. Underwood, MD, MBA,Joseph P. Newhouse, PhDJune 1st 2007
Relationship Between Generic and Preferred-brand Prescription Copayment Differentials and Generic Fill RateByDouglas E. Mager, MA,Emily R. Cox, PhDJune 1st 2007
Effect of a Medication Copayment Increase in Veterans With SchizophreniaByJohn E. Zeber, PhD,Kyle L. Grazier, PhD,Marcia Valenstein, MD,Frederic C. Blow, PhD,Paula M. Lantz, PhDJune 1st 2007
Effect of Copayments on Drug Use in the Presence of Annual Payment LimitsByGeorge Kephart, PhD,Chris Skedgel, MDE,Ingrid Sketris, PharmD,Paul Grootendorst, PhD,John Hoar, MPAJune 1st 2007
"Fiscally Responsible, Clinically Sensitive" Cost Sharing: Contain Costs While Preserving QualityByA. Mark Fendrick, MD,Michael E. Chernew, PhDMay 31st 2007
